Roche Holding AG (OTCMKTS:RHHBY) Given Average Rating of “Moderate Buy” by Analysts

Roche Holding AG (OTCMKTS:RHHBY) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, one has issued a buy recommendation and two have assigned a strong buy recommendation to the company.

A number of analysts have recently weighed in on RHHBY shares. Morgan Stanley started coverage on shares of Roche in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Sanford C. Bernstein raised shares of Roche to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, UBS Group upgraded Roche from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th.

Roche Trading Up 2.0 %

RHHBY stock opened at $43.89 on Friday. Roche has a twelve month low of $29.20 and a twelve month high of $43.92. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.26 and a quick ratio of 0.97. The firm has a 50 day simple moving average of $39.01 and a 200-day simple moving average of $38.49.

Hedge Funds Weigh In On Roche

Several large investors have recently added to or reduced their stakes in the company. Brooklyn Investment Group bought a new stake in Roche in the third quarter valued at $40,000. IHT Wealth Management LLC bought a new stake in Roche in the third quarter valued at $236,000. Verity Asset Management Inc. bought a new stake in Roche in the third quarter valued at $253,000. Canopy Partners LLC lifted its stake in Roche by 4.6% in the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock valued at $310,000 after buying an additional 344 shares during the last quarter. Finally, HighPoint Advisor Group LLC lifted its stake in Roche by 2.8% in the fourth quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company’s stock valued at $387,000 after buying an additional 304 shares during the last quarter.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.